Editas Medicine: Resetting Pipeline Just To Be Second To Market Again

2026-05-28 07:18:23 ET

Editas Medicine, Inc. ( EDIT ) has undergone a big pipeline reset in late 2024. Up to that point, they were focusing mainly on ex vivo gene therapy, specifically the lead asset reni-cel for sickle cell disease. Unlike many other companies that scrap their pipeline because the drug in question fails or does not work as expected, Editas was forced to make this decision based on something totally different. The problem was that competitors like Vertex Pharmaceuticals and Bluebird Bio beat Editas to the market with approved therapies. Management made the decision to pull the plug on EDIT-301 even though it has been performing very well in human trials (the RUBY Trial (Phase 1/2/3) and the EdiTHAL Trial (Phase 1/2)) because they realized that the drug would be entering an already saturated market, with no clear advantage over competition and an expensive manufacturing process....

Read the full article on Seeking Alpha

For further details see: